Learn about early-onset Alzheimer's through real stories of hope and breakthrough treatments that are changing lives of patients diagnosed before age ...

Alzheimer's disease begins with a long period during which abnormal amyloid and tau proteins build up in the brain without ...

"This is real progress," said Alzheimer’s Association President and CEO Dr. Joanne Pike in a statement shared with Fox News ...

The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

"These findings reveal a critical link between cellular stress and the neurotoxic effects of microglia in Alzheimer's disease." "Targeting this pathway may open up new avenues for treatment by ...

The Alzheimer’s Association — a Chicago-based nonprofit ... and greater opportunity to have more time. Having multiple treatment options is the kind of advancement we’ve all been waiting ...

The treatment is not a permanent fix for Alzheimer's dementia, Jing said ... It's important for them to know there are options out there." Offering this level of care in Lafayette is important ...

Dopamine’s involvement in Alzheimer’s treatment stems from its ability to stimulate the production of neprilysin, an enzyme crucial for breaking down beta-amyloid. Neprilysin acts as a natural ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January ...

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...

Blarcamesine is an orally once daily administered small molecule for the potential treatment of patients with Alzheimer’s disease. “The EMA filing acceptance for blarcamesine to review the ...